Survival rate and influencing factors of HIV/AIDS after highly active antiretroviral therapy in Yinzhou District
10.19485/j.cnki.issn2096-5087.2020.04.006
- VernacularTitle:鄞州区艾滋病抗病毒治疗患者生存率及影响因素分析
- Author:
WANG Bin
1
;
GONG Deguang
;
ZHU Jiequn
Author Information
1. Yinzhou Center for Disease Control and Prevention
- Publication Type:Journal Article
- Keywords:
acquired immune deficiency syndrome antiviral therapy survival analysis influencing factor
- From:
Journal of Preventive Medicine
2020;32(4):346-350
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the survival rate and its influencing factors of HIV/AIDS patients after antiviral therapy in Yinzhou District of Ningbo,so as to provide basis for AIDS prevention and control.
Methods:The data of HIV/AIDS patients who received highly active antiretroviral therapy（HAART）in Yinzhou District from May 2005 to December 2014 were retrieved from the national AIDS comprehensive prevention and control information system;the survival rate was calculated by life table and Kaplan-Meier analysis;the influencing factors for survival time was analyzed by a multivariate cox proportional risk regression model.
Results:Among 327 HIV/AIDS patients,twenty four were dead and three were lost. The average follow-up time was（5.63 ± 1.98）years. The cumulative survival rates of the subjects were 95%,92%,and 90% at 1,5,and 10 years after HAART. The Results of multivariate cox proportional risk regression analysis showed that patients who were at younger age when treatment begins（HR=1.053,95%CI: 1.001-1.108）,were transmitted by homosexual contact（HR=0.026,95%CI: 0.003-0.253）and by blood transmission（HR=0.043,95%CI: 0.006-0.309）,had high level of CD4+T lymphocyte at baseline（HR=0.993,95%CI: 0.988-0.998),and had viral load below the detection limit after six months of treatment（HR=0.028,95%CI: 0.009-0.084）were less likely to be dead.
Conclusions:The survival rate of HIV/AIDS patients after HAART is high,and is associated with the age when treatment begins,route of transmission,baseline CD4+T lymphocyte level and viral load after six months of treatment.
